[go: up one dir, main page]

BRPI0807597B8 - composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação - Google Patents

composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação

Info

Publication number
BRPI0807597B8
BRPI0807597B8 BRPI0807597A BRPI0807597A BRPI0807597B8 BR PI0807597 B8 BRPI0807597 B8 BR PI0807597B8 BR PI0807597 A BRPI0807597 A BR PI0807597A BR PI0807597 A BRPI0807597 A BR PI0807597A BR PI0807597 B8 BRPI0807597 B8 BR PI0807597B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
salt
combination
neuraminidase inhibitor
pyrazine derivative
Prior art date
Application number
BRPI0807597A
Other languages
English (en)
Inventor
Maekawa Masako
Original Assignee
Fujifilm Toyama Chemical Co Ltd
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Toyama Chemical Co Ltd, Toyama Chemical Co Ltd filed Critical Fujifilm Toyama Chemical Co Ltd
Publication of BRPI0807597A2 publication Critical patent/BRPI0807597A2/pt
Publication of BRPI0807597B1 publication Critical patent/BRPI0807597B1/pt
Publication of BRPI0807597B8 publication Critical patent/BRPI0807597B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinaçâo é descrita uma composição farmacêutica compreendendo um derivado de pirazina representado pela seguinte fórmula geral: [i] [em que r1 e r2 independentemente representam um átomo de hidrogênio ou um átomo de halogênio; e r3 representa um átomo de hidrogênio ou um grupo que protege amino] ou um sal do mesmo e pelo menos um inibidor da neuraminidase. a composição farmacêutica é usada para um tratamento incluindo o tratamento ou prevenção de influenza. também é descrito um método para usar estes componentes em combinação. o método é usado para um tratamento incluindo o tratamento ou prevenção de influenza.
BRPI0807597A 2007-02-16 2008-02-14 composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação BRPI0807597B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007035975 2007-02-16
JP2007-035975 2007-02-16
PCT/JP2008/052425 WO2008099874A1 (ja) 2007-02-16 2008-02-14 ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法

Publications (3)

Publication Number Publication Date
BRPI0807597A2 BRPI0807597A2 (pt) 2014-05-06
BRPI0807597B1 BRPI0807597B1 (pt) 2021-03-02
BRPI0807597B8 true BRPI0807597B8 (pt) 2021-05-25

Family

ID=39690101

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807597A BRPI0807597B8 (pt) 2007-02-16 2008-02-14 composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação

Country Status (21)

Country Link
US (1) US8759354B2 (pt)
EP (1) EP2123276B1 (pt)
JP (1) JP5255456B2 (pt)
KR (1) KR101479083B1 (pt)
CN (1) CN101610772B (pt)
AU (1) AU2008215397B2 (pt)
BR (1) BRPI0807597B8 (pt)
CA (1) CA2677905C (pt)
CY (1) CY1113435T1 (pt)
DK (1) DK2123276T3 (pt)
ES (1) ES2396595T3 (pt)
HR (1) HRP20130111T1 (pt)
IL (1) IL200285A (pt)
MX (1) MX2009008779A (pt)
NZ (1) NZ578989A (pt)
PL (1) PL2123276T3 (pt)
PT (1) PT2123276E (pt)
RU (1) RU2463051C2 (pt)
SI (1) SI2123276T1 (pt)
WO (1) WO2008099874A1 (pt)
ZA (1) ZA200905536B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417617A4 (en) * 2009-04-09 2012-09-26 Lg Electronics Inc DISPLAY APPARATUS
JP5947289B2 (ja) * 2010-05-10 2016-07-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
US20130217708A1 (en) 2010-09-30 2013-08-22 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
RS54408B1 (en) 2010-09-30 2016-04-28 Toyama Chemical Co. Ltd. Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2996685B1 (en) * 2013-05-14 2019-03-27 Biocryst Pharmaceuticals, Inc. Anti-influenza compositions and methods
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
CN104817511B (zh) * 2015-04-27 2017-04-19 济南大学 一种丁烯二酸酐制备法匹拉韦关键中间体的方法
SG11201804348SA (en) * 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
JP7369143B2 (ja) * 2018-12-25 2023-10-25 富士フイルム富山化学株式会社 ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤
WO2021241613A1 (ja) 2020-05-27 2021-12-02 富士フイルム富山化学株式会社 ピラジン誘導体とチオプリン誘導体を組み合わせてなるｒｎａウイルス感染症治療剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197437A (ja) * 1988-01-29 1989-08-09 Dso Pharmachim 抗ウイルス薬
IL141150A (en) * 1998-08-20 2005-08-31 Toyama Chemical Co Ltd Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing them
JP4370164B2 (ja) 2001-08-14 2009-11-25 富山化学工業株式会社 新規なウイルス増殖阻害・殺ウイルス方法および新規なピラジンヌクレオチド・ピラジンヌクレオシド類似体
JP2005354833A (ja) * 2004-06-11 2005-12-22 Fujinon Corp アクチュエータ
JP4689989B2 (ja) * 2004-08-27 2011-06-01 オリンパス株式会社 振動波リニアモータ及びそれを用いたレンズ装置
DE102008031715A1 (de) 2008-07-04 2010-01-07 Henkel Ag & Co. Kgaa Haarkonditionierende Mittel mit Imidazolinen

Also Published As

Publication number Publication date
KR20090121289A (ko) 2009-11-25
PT2123276E (pt) 2013-01-16
US20100087447A1 (en) 2010-04-08
MX2009008779A (es) 2009-11-05
NZ578989A (en) 2011-07-29
IL200285A0 (en) 2010-04-29
BRPI0807597B1 (pt) 2021-03-02
IL200285A (en) 2014-06-30
CN101610772A (zh) 2009-12-23
AU2008215397A1 (en) 2008-08-21
BRPI0807597A2 (pt) 2014-05-06
ZA200905536B (en) 2010-10-27
RU2009134516A (ru) 2011-03-27
PL2123276T3 (pl) 2013-04-30
CN101610772B (zh) 2013-01-16
RU2463051C2 (ru) 2012-10-10
EP2123276B1 (en) 2012-11-28
JPWO2008099874A1 (ja) 2010-05-27
AU2008215397B2 (en) 2012-09-06
EP2123276A1 (en) 2009-11-25
EP2123276A4 (en) 2011-05-18
DK2123276T3 (da) 2013-01-02
CA2677905C (en) 2015-03-24
US8759354B2 (en) 2014-06-24
JP5255456B2 (ja) 2013-08-07
WO2008099874A1 (ja) 2008-08-21
ES2396595T3 (es) 2013-02-22
KR101479083B1 (ko) 2015-01-07
CY1113435T1 (el) 2016-06-22
HRP20130111T1 (hr) 2013-02-28
SI2123276T1 (sl) 2013-03-29
CA2677905A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
BRPI0807597B8 (pt) composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação
CY1120778T1 (el) Αναστολεις αντιγραφης ιων γριπης
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
BR112012033770A2 (pt) novo derivado de nicotinamida ou sal do mesmo
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
BRPI1010768C8 (pt) composto de fórmula (i)
NO20090628L (no) Pyridizinon derivativater
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BR112014001018A2 (pt) derivado de azabenzimidazol tendo atividade de ativação de ampk
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
BRPI0507198A (pt) derivados de bisariluréia
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
CU24030B1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF